Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infection

Immunological analyses in this laboratory and others have suggested that a nonrecurrent HSV seropositive immune status is more closely correlated with a type 1 T helper cell (Th1) response characterized by elevated levels of interferon-γ and IL2 rather than high titers of virus-specific antibodies....

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 13; no. 17; pp. 1706 - 1712
Main Authors:	York, Laura J., Giorgio, David P., Mishkin, Eric M.
Format:	Journal Article
Language:	English
Published:	Oxford Elsevier Ltd 1995 Elsevier
Subjects:	Adjuvants, Immunologic - pharmacology Adjuvants, Immunologic - therapeutic use Animals Antibody Specificity Biological and medical sciences Female Fundamental and applied biological sciences. Psychology Herpes Simplex - immunology Herpes Simplex - therapy herpes simplex virus 1 Herpesvirus 1, Human - immunology Herpesvirus 2, Human - immunology HSV vaccine Immunity, Cellular - drug effects Immunoglobulin G - biosynthesis Immunoglobulin G - classification Immunotherapy Mice Mice, Inbred BALB C Microbiology Neutralization Tests Recurrence Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Viral Envelope Proteins - immunology Viral Envelope Proteins - pharmacology Viral Envelope Proteins - therapeutic use Viral Vaccines - administration & dosage Viral Vaccines - immunology Virology Immunotherapy HSV vaccine Immunostimulation Immune response Immunomodulation Herpesviridae Alphaherpesvirinae Rodentia Glycoproteins Cellular immunity Vaccine Recurrent Infection Virus Vertebrata Mammalia Treatment Herpesvirus hominis 1 Immunogenicity Mouse Herpesvirus hominis 2 Viral disease Virus envelope
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Immunological analyses in this laboratory and others have suggested that a nonrecurrent HSV seropositive immune status is more closely correlated with a type 1 T helper cell (Th1) response characterized by elevated levels of interferon-γ and IL2 rather than high titers of virus-specific antibodies. Effective intervention with an immunotherapeutic vaccine may require modulation of the regulatory network of T helper cells such that there is selective restimulation and expansion of the Th1 response. We have established a murine model for assessing the immunomodulatory capacity of an HSV glycoprotein subunit vaccine in animals with pre-existing herpes immunity. Animals were infected with varying doses of HSV1 and then administered glycoprotein D (gD) vaccine adjuvanted with aluminum phosphate at 3-week intervals. Observed changes in serological and cellular responses indicated that administration of subunit vaccine adjuvanted with aluminum phosphate could shift a dominant Th1 response, induced by sensitization with live HSV, towards a Th2 profile of activity. These data suggest that use of aluminum based adjuvants will not selectively stimulate Th1-associated responses and alternative adjuvants may be required for effective use of subunit vaccine in an immunotherapeutic indication in humans.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0264-410X 1873-2518
DOI:	10.1016/0264-410X(95)00104-9